Motor complications in Parkinson disease: Clinical manifestations and management

被引:45
作者
Bhidayasir, Roongroj [1 ,2 ,3 ]
Truong, Daniel D. [3 ]
机构
[1] Chulalongkorn Univ Hosp, Div Neurol, Chulalongkorn Comprehens Movement Disorders Ctr, Bangkok 10330, Thailand
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA
[3] Parkinsons & Movement Disorder Inst, Fountain Valley, CA 92708 USA
关键词
Parkinson disease; motor complications; dyskinesia; complex fluctuations; dopaminomimetic therapy;
D O I
10.1016/j.jns.2007.08.028
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Long-term dopaminomimetic therapy, not limited to levodopa, is complicated by the emergence of variations of motor response in a majority of Parkinson disease (PD) patients. These variations can occur in different forms, as early wearing off during the initial stage of motor complications, dyskinesias in the intermediate stage, and complex fluctuations in the advanced stage. Considered to be a major source of disability in advanced PD patients, recognition of these complications is critical in order to develop different strategies designed not only to treat these problems when they develop, but also to prevent troublesome complications associated with potential risk factors. In this article, authors classify a wide clinical spectrum of motor complications into different stages as the disease progresses through the treatment. A number of strategies are proposed in order to manage these complications as well as to avoid them. Better understanding of these potential complications will result in better management of these problems and lessen the disability associated with advanced PD. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:204 / 215
页数:12
相关论文
共 155 条
[1]   Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa [J].
Adler, CH ;
Singer, C ;
O'Brien, C ;
Hauser, RA ;
Lew, MF ;
Marek, KL ;
Dorflinger, E ;
Pedder, S ;
Deptula, D ;
Yoo, K .
ARCHIVES OF NEUROLOGY, 1998, 55 (08) :1089-1095
[2]   Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature [J].
Ahlskog, JE ;
Muenter, MD .
MOVEMENT DISORDERS, 2001, 16 (03) :448-458
[3]   CONTROLLED-RELEASE SINEMET (CR-4) - A DOUBLE-BLIND CROSSOVER STUDY IN PATIENTS WITH FLUCTUATING PARKINSONS-DISEASE [J].
AHLSKOG, JE ;
MUENTER, MD ;
MCMANIS, PG ;
BELL, GN ;
BAILEY, PA .
MAYO CLINIC PROCEEDINGS, 1988, 63 (09) :876-886
[4]  
[Anonymous], 1997, Ann Neurol, V42, P747
[5]   Tolcapone and fulminant hepatitis [J].
Assal, F ;
Spahr, L ;
Hadengue, A ;
Rubbici-Brandt, L ;
Burkhard, PR .
LANCET, 1998, 352 (9132) :958-958
[6]   PERMANENT HUMAN PARKINSONISM DUE TO 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE (MPTP) - 7 CASES [J].
BALLARD, PA ;
TETRUD, JW ;
LANGSTON, JW .
NEUROLOGY, 1985, 35 (07) :949-956
[7]   INFLUENCE OF MEAL INGESTION TIME ON PHARMACOKINETICS OF ORALLY-ADMINISTERED LEVODOPA IN PARKINSONIAN-PATIENTS [J].
BARUZZI, A ;
CONTIN, M ;
RIVA, R ;
PROCACCIANTI, G ;
ALBANI, F ;
TONELLO, C ;
ZONI, E ;
MARTINELLI, P .
CLINICAL NEUROPHARMACOLOGY, 1987, 10 (06) :527-537
[8]  
Bergmann K J, 1987, Adv Neurol, V45, P463
[9]   Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies [J].
Bezard, E ;
Brotchie, JM ;
Gross, CE .
NATURE REVIEWS NEUROSCIENCE, 2001, 2 (08) :577-588
[10]   DOES LEVODOPA AGGRAVATE PARKINSONS-DISEASE [J].
BLIN, J ;
BONNET, AM ;
AGID, Y .
NEUROLOGY, 1988, 38 (09) :1410-1416